Tsai M.-H.Huang Y.-C.Yen M.-H.Li C.-C.Chiu C.-H.Lin P.-Y.Lin T.-Y.LUAN-YIN CHANG2020-12-152020-12-1520060022-3476https://www.scopus.com/inward/record.uri?eid=2-s2.0-30744441907&doi=10.1016%2fj.jpeds.2005.08.024&partnerID=40&md5=528bec57838b1b6adfa2e165f4c69e25https://scholars.lib.ntu.edu.tw/handle/123456789/525654Objective: To determine whether different brands of intravenous immunoglobulin (IVIG) administered to children with Kawasaki disease (KD) result in different outcomes. Study design: We analyzed children with KD and divided them into 4 groups according to the brand of IVIG. A coronary artery abnormality (CAA) was defined as having a lumen diameter (inner border to inner border) of ?3 mm in KD cases <5 years old and ?4 mm in cases ?5 years old, and giant aneurysm was defined as a lumen diameter ?8 mm. Patients were considered nonresponsive to IVIG therapy if fever persisted longer than 2 days after completion of treatment and needed retreatment with IVIG. Results: We collected 437 cases, 29 (6.6%) were nonresponsive, 17 (3.9%) had CAA at convalescence, and 3 (0.7%) had giant aneurysm, 2 of whom had development of myocardial infarcts. Patients receiving Brand C IVIG, prepared with β-propiolactone, had higher rates (10%, 9/93, P = .01) of CAA at convalescence and nonresponsiveness (13%, 12/93, P = .001); giant aneurysm occurred in 3/93 (3%) receiving Brand C IVIG and in 0/344 who received the other 3 brands (P = .008). Conclusions: IVIG, prepared with β-propiolactone, was most significantly associated with nonresponsiveness, CAA at convalescence, and giant aneurysm. Physicians should be cautious when using IVIG prepared with β-propiolactone or enzyme digestion to treat KD. Copyright ? 2006 Elsevier Inc. All rights reserved.[SDGs]SDG3acetylsalicylic acid; immunoglobulin; immunoglobulin G; propiolactone; artery diameter; article; child; convalescence; coronary artery aneurysm; coronary artery disease; demography; disease course; echocardiography; heart infarction; human; infant; major clinical study; male; mucocutaneous lymph node syndrome; priority journal; retreatment; symptom; treatment outcome; treatment response; Child; Child, Preschool; Convalescence; Coronary Aneurysm; Female; Fever; Humans; Immunoglobulins, Intravenous; Infant; Male; Mucocutaneous Lymph Node Syndrome; Treatment Outcomejournal article10.1016/j.jpeds.2005.08.024164235952-s2.0-30744441907